Investment Thesis
Anika Therapeutics is a medtech company with a strong balance sheet but deteriorating operational performance. Declining revenue (-5.9% YoY), persistent operating losses (-18.5% margin), and negative free cash flow (-$6.3M) indicate fundamental business challenges despite solid liquidity and low leverage. The company must stabilize revenue and achieve profitability to justify investment.
Strengths
- Strong balance sheet with low leverage (Debt/Equity: 0.19x) providing financial flexibility
- Excellent liquidity position (Current Ratio: 4.46x, Quick Ratio: 3.37x) with $41M cash reserves
- Healthy gross margins (64.2%) indicating competitive product positioning and pricing power
Risks
- Declining revenue trend (-5.9% YoY) suggests loss of market share or demand weakness
- Significant operating losses (-$5.5M) and negative net margin (-17.1%) indicate operational inefficiency
- Negative operating cash flow (-$4.8M) and free cash flow (-$6.3M) showing cash burn despite adequate reserves
Key Metrics to Watch
- Revenue stabilization and return to growth
- Operating cash flow improvement toward positive territory
- Path to operating profitability and operating margin expansion
Financial Metrics
Revenue
29.6M
Net Income
-5.1M
EPS (Diluted)
$-0.37
Free Cash Flow
-6.3M
Total Assets
179.4M
Cash
41.0M
Profitability Ratios
Gross Margin
64.2%
Operating Margin
-18.5%
Net Margin
-17.1%
ROE
-3.8%
ROA
-2.8%
FCF Margin
-21.2%
Balance Sheet & Liquidity
Current Ratio
4.46x
Quick Ratio
3.37x
Debt/Equity
0.19x
Debt/Assets
0.0%
Interest Coverage
N/A
Long-term Debt
25.0M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-06T14:22:26.996152 |
Data as of: 2026-03-31 |
Powered by Claude AI